ASH 2023 | Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, share their key highlights in amyloidosis from this year’s ASH Annual Meeting. The experts first discuss updates being made in the diagnosis of patients with light chain (AL) amyloidosis, and comment on the potential benefits of these novel approaches. Following this, Dr Sanchorawala and Dr Wechalekar discuss studies exploring the safety and efficacy of immunotherapeutic agents, including belantamab mafodotin, birtamimab, and CAEL-101, in patients with amyloidosis. Other topics addressed in this discussion include novel staging systems being used to risk stratify patients in this disease setting. This discussion took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanchorawala:
Consultancy: Janssen, Alexion, Prothena, Celgene, Takeda, Abbvie, Regeneron, Pfizer, AstraZeneca
Honoraria: Janssen, Alexion, Prothena, Celgene, Takeda, Abbvie, Regeneron, Pfizer, AstraZeneca
Membership on Board of Directors or advisory committee: Janssen, Alexion, Prothena, Celgene, Takeda, Abbvie, Regeneron, Pfizer, AstraZeneca
Research Funding: Janssen, Alexion, Prothena, Celgene, Takeda, Abbvie, Regeneron, Pfizer, AstraZeneca
Wechalekar:
Travel support: Takeda
Honoraria: GSK, Janssen, Attralus, Alexion
Consultancy: Alexion, Attralus, Janssen, Prothena
